Constipation – European Clinical Trials Information Network

Safety and tolerability study of sodium hydrogen carbonate and sodium dihydrogen phosphate suppository treatment in adult patients with chronic constipation

Wed, 29 Apr 2026 15:06:20 +0000

This clinical study examines the effects of Lecicarbon® E CO2-Laxans in people with chronic constipation. Chronic constipation is a condition where a person has two or fewer bowel movements per week, along with symptoms such as hard stools, incomplete evacuation feelings, or straining during bowel movements that persist for at least 6 months.

The purpose of this study is to evaluate how safe and well-tolerated Lecicarbon® E CO2-Laxans is when used as a long-term treatment. The medication is given as a suppository for rectal use and contains two active ingredients: sodium hydrogen carbonate and sodium dihydrogen phosphate. Patients may receive up to two units daily for a treatment period of up to 4 weeks.

During the study, participants will need to keep a diary to track their bowel movements and symptoms. The study will also look at how the treatment affects constipation symptoms and overall quality of life. The medication works by producing carbon dioxide, which helps stimulate bowel movements.

Study on Preventing Constipation in Critically Ill Children Using Macrogol 3350, Sodium Hydrogen Carbonate, Potassium Chloride, and Sodium Chloride

Wed, 29 Apr 2026 15:02:56 +0000

This clinical trial is focused on studying the prevention of constipation in critically ill children. Constipation is a common issue where a person has difficulty in passing stools. The treatment being tested in this study is a medication called Movicol Pediátrico Sabor Neutro, which is an oral solution containing a combination of substances: sodium hydrogen carbonate, potassium chloride, sodium chloride, and macrogol 3350. These ingredients work together to help soften stools and make them easier to pass.

The purpose of the study is to test how effective this treatment is in preventing constipation in children who are critically ill. The study will involve children who are admitted to the Pediatric Intensive Care Unit (PICU) and are at high risk of developing constipation. Participants will receive either the treatment or a placebo, and their stool output will be monitored to assess the treatment’s effectiveness. The study will also look at the safety of the treatment by monitoring any adverse events and assessing stool consistency using a tool called the Bristol scale.

The study will take place over a period of time, with children being observed for changes in their bowel movements. The goal is to determine if the treatment can successfully prevent constipation in these vulnerable patients, improving their comfort and overall health during their stay in the PICU.

Study on Linaclotide for Treating Functional Constipation in Children Aged 6 Months to Less Than 2 Years

Wed, 29 Apr 2026 14:26:36 +0000

This clinical trial is focused on studying Functional Constipation in young children aged 6 months to less than 2 years. Functional Constipation is a condition where children have difficulty passing stools, which can lead to discomfort and other symptoms. The study will use a medication called Linaclotide, which is taken orally in the form of a capsule. Linaclotide works as an agonist of guanylate cyclase C (GCC), which means it helps to increase fluid in the intestines and speed up the movement of stools through the gut.

The purpose of the study is to find a safe and effective dose of Linaclotide for treating Functional Constipation in this age group. The study will be conducted over a period of 4 weeks. During this time, participants will receive either Linaclotide or a placebo. The study will monitor changes in the frequency and consistency of bowel movements, as well as any straining during bowel movements, to assess the effectiveness of the treatment.

Participants will be closely observed to ensure their safety and to determine the best dose of Linaclotide that provides relief from constipation symptoms. The study aims to improve the quality of life for young children suffering from Functional Constipation by identifying a treatment that is both safe and effective.

Study on Linaclotide for Treating Functional Constipation in Children Aged 2 to 5 Years

Wed, 29 Apr 2026 14:23:39 +0000

This clinical trial is focused on studying Functional Constipation in young children aged 2 to 5 years. The study will evaluate the effects of a medication called Linaclotide, which is taken in capsule form. Linaclotide works as an agonist of guanylate cyclase C (GC-C), which means it helps to stimulate certain processes in the body that can improve bowel movements. The trial will compare the effects of Linaclotide with a placebo to understand its safety and effectiveness in treating Functional Constipation in children.

The purpose of the study is to assess how well Linaclotide works over a 12-week period and to ensure it is safe for long-term use. The study is divided into two parts. In the first part, children will receive either Linaclotide or a placebo for 12 weeks. During this time, caregivers will observe changes in the frequency of bowel movements, stool consistency, and any straining during bowel movements. In the second part, children who have completed the first part will continue to receive Linaclotide to further evaluate its long-term safety.

This trial aims to provide valuable information on the treatment of Functional Constipation in young children, potentially offering a new option for managing this condition. The study will help determine if Linaclotide can be a safe and effective treatment for improving bowel habits in children with Functional Constipation.